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Lavage with diluted surfactant 
as a treatment option for atelectasis 
in pediatric intensive care patients
Maja Karaman Ilić1, Goran Madžarac2, Irena Babić3, Boris Milavić4
The aim of this study was to assess the eff ect of fi beroptic aspiration and diluted surfactant administration on aff ected lungs in 
children with atelectasis. A convenience sample of 18 mechanically ventilated children were analyzed in this single center prospec-
tive study. The children had fi rst been treated unsuccessfully by respiratory physical therapy, after which they underwent fi beroptic 
aspiration. After aspiration, nine children were randomly selected to receive therapeutic lavage with diluted porcine surfactant; the 
remaining nine received the same quantity of saline solution. Several parameters of lung function, including positive end-expiratory 
pressure (PEEP) and oxygenation index (OI), as well as lung x-ray images were determined before aspiration and lavage, then at 6 
and 12 h after lavage. In both groups, most of the measured parameters showed improvement from baseline at 6 h after treatment. 
Improvement was even more signifi cant 12 h after treatment. The surfactant group showed signifi cant improvement in comparison 
to the saline group. The impact of surfactant administration was most visible on the following parameters 12 h after treatment 
(p<0.001 in all cases): PEEP 5.22 (SD 0.44) in the saline group vs. 3.44 (SD 0.73) in the surfactant group; OI 3.84 (SD 1.13) vs. 2.1 (SD 
0.38); and mean airway pressure (MAP) 8.56 (SD 0.88) vs. 6.33 (SD 0.5). In conclusion, fi beroptic aspiration is an effi  cient treatment in 
pediatric intensive care patients. The observed benefi cial eff ects of therapeutic lavage with diluted surfactant should be confi rmed 
prospectively in a larger number of patients.
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INTRODUCTION
Atelectasis refers to the lack of gas exchange in collapsed, 
airless regions of the lung (1). The condition itself is not a 
disease, but is associated with several pulmonary and chest 
disorders and is a symptom of the underlying disease (2). 
Clinical manifestations of atelectasis depend on the under-
lying cause, as well as on the degree of volume loss within 
the lung. When atelectasis is relatively small and associated 
with little physiological impairment, there may be no signs 
or symptoms. In massive unilateral atelectasis, however, tra-
cheal deviation and a shift in heart sounds towards the atel-
ectatic side may occur (3).
The standard treatment for atelectasis is respiratory physical 
therapy, including percussion, vibration, aspiration, aerosol-
ized bronchodilators and positional drainage. Fiberoptic 
aspiration, alone or with therapeutic saline lavage, is used 
when these procedures are ineff ective. Bronchoscopic aspi-
ration is a safe bedside procedure, even in pediatric popula-
tion (4, 5).
Lobar atelectasis is frequently seen in pediatric patients un-
dergoing mechanical ventilation (6). At least 8% of children 
on mechanical ventilation develop pulmonary atelectasis, 
with a concomitant increase in the morbidity and length of 
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hospitalization (7). The most common types of atelectasis in 
children are resorption atelectasis following airway obstruc-
tion or adhesive atelectasis due to surfactant defi ciency or 
dysfunction (8). In cases of the latter, surfactant administra-
tion as supplementary therapy may help minimize changes 
in surface tension and improve mucus transport within the 
narrow pediatric airways (4, 9). According to Strohmaier 
(10), lavage with diluted surfactant may not only replenish 
the missing endogenous surfactant, but it may also remove 
pathologic material more eff ectively than saline lavage be-
cause the washing agent is more uniformly distributed.
The eff ect of therapeutic lavage with diluted surfactant is 
still questionable. Several studies have shown lavage with 
diluted surfactant to be more therapeutically eff ective than 
conventional bolus or aerosol therapy (11-13). However, 
studies on pediatric and adult patients with diff erent indica-
tions for exogenous surfactant application have given con-
tradictory results (14-22). For example, the use of surfactant 
shows promise for treating severe bronchiolitis and acute 
respiratory distress syndrome (ARDS) (23), but its use in pa-
tients with bronchopneumonia remains controversial.
The present study was designed to investigate whether as-
piration followed by therapeutic lavage with diluted exog-
enous surfactant can eff ectively treat atelectasis in pediatric 
patients on long-term ventilation.
MATERIALS AND METHODS
Patient recruitment
This prospective study was carried out in the intensive care 
unit (ICU) of the Zagreb Children’s Hospital. The Hospital 
Ethics Committee approved the study, and a written in-
formed consent was obtained from the parents. Patient 
characteristics (demographic data and diagnoses) are shown 
in Table 1.
Out of 42 children mechanically ventilated in the ICU during 
the study period, 18 of 25 patients that developed lobar at-
electasis were enrolled in the study. Inclusion criteria were 
pediatric status, presence of atelectasis, and mechanical 
ventilation longer than two weeks.
Atelectasis was diagnosed based on clinical and radiologi-
cal criteria. The clinical criteria were fever, crepitation, partial 
pressure of carbon dioxide (PaCO2) ≥45 mm Hg (6 kPa), peak 
inspiratory pressure (PIP) ≥25, and partial pressure of arterial 
oxygen/fraction of inspired oxygen ratio (PaO2/FiO2) ≤300. 
Radiological criteria included opacifi cation, a shift of the 
mediastinum, displacement of the interlobar fi ssure and el-
evated diaphragm. Laboratory investigations included com-
plete blood count, blood cultures, and culture of airway se-
cretions.
Procedures
Patients were randomly assigned to either of the two groups 
using closed envelopes. Both groups were ventilated with a 
Dräger Medical EVITA 4 (Lübeck, Germany). Peak inspiratory 
pressure (PIP) and positive end-expiratory pressure (PEEP) 
were adjusted to achieve a tidal volume of 7-8 mL/kg body 
weight.
No food was given to children through their nasogastric 
tube for at least 4 h prior to bronchoscopy. During the aspi-
ration and lavage, inspiratory oxygen fraction (FiO2) was 1.0. 
Procedures were performed through tracheostomy or en-
dotracheal tube with an Olympus BF-3C30 bronchoscope. 
Lidocaine (2%, maximum dose of 1 mg/kg) was used for lo-
cal anesthesia of the carina and to prevent straining. Oxy-
gen saturation (SpO2), end-tidal carbon dioxide in expired 
air (etCO2) and invasive arterial pressure (ABP) were moni-
tored throughout the procedure. Multiple intravenous (IV) 
accesses were secured. If SpO2 fell below 85%, the proce-
dures were stopped until the level recovered. All procedures 
were performed in the ICU or the operating room.
After fi beroptic aspiration, therapeutic lavage of the aff ect-
ed area was carried out using solutions pre-warmed to body 
temperature. Children in the control group received isoton-
ic saline, while those in the surfactant group received an 
equal volume of porcine surfactant diluted in saline solu-
tion (5 mg Curosurf/mL; Curosurf®, Chiesi, Italy). The whole 
amount of fl uid surfactant was given instantly in the main bron-
chus of the aff ected lung. The mean volume (SD) given to 
each group was 34.3 (SD 13.76) mL, corresponding to a 
mean (SD) of 3.199 (0.411) mL/kg body weight. The mean 
amount (SD) of surfactant delivered to the experimental 
group was 15.66 (SD 2.33) mg Curosurf/kg body weight.
Measurements
Several gas exchange and pulmonary mechanic parameters 
were measured before and after aspiration and lavage: PIP 
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in cm H2O, PEEP in cm H2O, PaO2/FiO2, oxygenation index 
(OI), PaCO2 in mm Hg, and mean airway pressure (MAP) in 
cm H2O. These measurements were made before treatment 
(baseline) and at 6 and 12 h after treatment. During the ob-
servation period, we minimized aspiration of the airways in 
order to keep the lavage solution at the site of action.
Descriptive lung x-ray evaluations were carried out at base-
line and 12 h after treatment. Radiograms were indepen-
dently assessed by two radiologists blinded to patient as-
signments.
Statistics
ANOVA tests were performed to determine signifi cant dif-
ferences in mean values between the study groups. Depen-
dent-sample t-tests were used to test diff erences in mean 
values between baseline and 6 h post-treatment, as well as 
between baseline and 12 h post-treatment. Independent-
sample t-tests were used to test diff erences in mean values 
between the control and experimental group for each of 
the three sets of measurements separately (baseline, 6 h 
post-treatment and 12 h post-treatment).
RESULTS
Lung x-ray evaluations were carried out at baseline and 12 h 
after treatment. Since the evaluations were qualitative, they 
were diffi  cult to analyze statistically. Chest x-ray analysis in-
dicated improvements in both groups, ranging from 20% to 
90%. Several lung function parameters were measured, in-
cluding PIP (cm H2O), PEEP (cm H2O), PaO2 (mm Hg)/FiO2, OI, 
SpO2, PaCO2 (mm Hg), and MAP (cm H2O). The two groups 
did not diff er signifi cantly in any of the parameters at base-
line (Table 2).
Both groups showed signifi cant improvement in multiple 
lung function parameters between baseline and 6 h after 
treatment, which increased further by 12 h post-treatment. 
In the control group, PaO2/FiO2, OI, and MAP signifi cantly 
improved from 6 h to 12 h after treatment (Table 3). By 12 h 
post-treatment, all measured parameters improved signifi -
cantly compared to baseline. In the experimental group, 
most of the parameters were signifi cantly better at 6 h as 
compared to baseline: PIP, PEEP, PaO2/FiO2, PaCO2, OI, and 
MAP (Table 4). Most of the measured parameters in this 
group further improved signifi cantly between 6 h and 12 h 
post-treatment: PIP, PEEP, PaO2/FiO2, OI and MAP. By 12 h 
post-treatment, all the measured parameters showed sig-
nifi cant improvement compared to baseline.
TABLE 2. Comparison of baseline lung function parameters between 





PIP (cm H2O) 29.11 29.56
PEEP (cm H2O) 6.44 6.56
PaO2/FiO2 (mm Hg) 210.18 205.97
OI 7.13 7.20
SpO2 93.22 93.56
PaCO2 (mm Hg) 63.00 56.44
MAP (cm H2O) 14.44 14.67
PIP = peak inspiratory pressure; PEEP = positive end expiratory pressure; 
PaO2/FiO2 = partial pressure of arterial oxygen/fraction of inspired oxygen 
ratio; OI = oxygenation index; SpO2 = oxygen saturation; PaCO2 = partial 
pressure of carbon dioxide; MAP = mean airway pressure
TABLE 3. Comparison of lung function parameters in control group 
before and after treatment
Baseline 
measurement 
6 h after 
treatment
12 h after 
treatment
PIP (cm H2O) 29.11 26.67
a 26.33b
PEEP (cm H2O) 6.44 5.22
a 5.22a
PaO2/FiO2 (mm Hg) 210.18 226.62
a 238.65a 1
OI 7.13 4.74b 3.84b 1
SpO2 93.22 96.67
a 97.00a
PaCO2 (mm Hg) 63.00 57.56
a 55.56a
MAP (cm H2O) 14.44 10.67
b 8.56b 2
PIP = peak inspiratory pressure; PEEP = positive end expiratory pressure; 
PaO2/FiO2 = partial pressure of arterial oxygen/fraction of inspired oxygen 
ratio; OI = oxygenation index; SpO2 = oxygen saturation; PaCO2 = partial 
pressure of carbon dioxide; MAP = mean airway pressure
astatistical diff erence when compared to the baseline measurement 
p<0.01; bstatistical diff erence when compared to the baseline 
measurement p<0.001; 1statistical diff erence between second and third 
measurement p<0.05; 2statistical diff erence between second and third 
measurement p<0.001
TABLE 4. Comparison of lung function parameters in surfactant group 
before and after treatment
Baseline 
measurement
6 h after 
treatment
12 h after 
treatment
PIP (cm H2O) 29.56 24.67
b 24.00b 1
PEEP (cm H2O) 6.56 4.67
b 3.44b 2
PaO2/FiO2 (mm Hg) 205.97 251.94
a 297.67b 3
OI 7.20 3.76b 2.10b 3
SpO2 93.56 98.00
a 98.67a
PaCO2 (mm Hg) 56.44 43.44
b 41.33b
MAP (cm H2O) 14.67 9.22
b 6.33b 3
PIP-peak inspiratory pressure, PEEP- positive end expiratory pressure, 
PaO2/FiO2- partial pressure of arterial oxygen/fraction of inspired oxygen 
ratio, OI- oxygenation index, SpO2- oxygen saturation, PaCO2- partial 
pressure of carbon dioxide, MAP- mean airway pressure
astatistical diff erence when compared to the baseline measurement 
p<0.01; bstatistical diff erence when compared to the baseline 
measurement p<0.001; 1statistical diff erence between second and third 
measurement p<0.05; 2statistical diff erence between second and third 
measurement p<0.01; 3statistical diff erence between second and third 
measurement p<0.001
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Comparisons were then carried out between the control 
and surfactant groups to determine whether the surfactant 
gave signifi cantly diff erent outcomes. For most of the lung 
function parameters, values were signifi cantly better in the 
surfactant group than in the control group at both 6 h and 
12 h post-treatment (Table 5). At 6 h after treatment, the 
surfactant group showed signifi cantly better values of PIP, 
OI, PaCO2 and MAP. By 12 h after treatment, the surfactant 
group showed better values of these parameters, as well as 
of PEEP and PaO2/FiO2.
DISCUSSION
This study was designed to investigate whether therapeutic 
lung lavage with diluted surfactant can improve treatment 
of atelectasis in pediatric patients. The results showed that, 
although both surfactant and control groups showed im-
provement in lung function parameters at 6 h post-treat-
ment and even more by 12 h, the improvement was greater 
in the surfactant group. In particular, PIP, PEEP, OI, PaCO2 and 
MAP appeared to improve with surfactant treatment. These 
values were signifi cantly lower than in the control group at 
both 6 h and 12 h post-treatment.
The fact that mechanical cleaning of the airways by itself 
was suffi  cient to improve lung function in the control group, 
together with the fact that the surfactant group showed 
greater recovery of lung function, suggests that atelectasis 
in our patients was partly resorptive due to airway obstruc-
tion and partly adhesive due the lack or dysfunction of sur-
factant.
The driving force for alveolar opening during inspiration is 
PIP (24, 25). PEEP, in contrast, appears to measure the force 
to maintain alveolar patency (24, 26-28). Maintaining high 
PIP and PEEP in order to open and stabilize collapsed alveo-
li can produce over-distention of healthy alveoli due to the 
variability in alveolar response (29, 30). This can result in 
barotrauma, which should be avoided. Therefore, in the 
present study, we sought to achieve suffi  cient PEEP and 
moderate PIP to ensure adequate oxygenation. At the same 
time, we sought to avoid high PEEP levels that would inter-
fere with hemodynamic stability or aff ect the central ner-
vous system function. Achieving a reduction in PEEP is par-
ticularly important in hemodynamically unstable patients 
and in children with elevated intracranial pressure, regard-
less of its cause. A total of 6 (67%) and 7 (78%) patients 
in our control and surfactant groups, respectively, fell into 
these two categories.
In the present study, atelectasis treatment was considered 
successful on the basis of improved oxygenation, as mea-
sured by increased SpO2; a decrease in OI, PIP, PEEP, MAP 
and PaCO2; and an increase in the PaO2/FiO2
 (P/F) ratio. In 
atelectasis, blood fl ow is shunted through non-ventilated 
areas. When ventilation is restored, PaO2 and SpO2 increase, 
and the inspired FiO2 may fall. OI, which is the ratio between 
the amount of oxygen delivered to the lungs and the 
amount diff using into the blood, may be the best indicator 
of clinical improvement because it integrates airway pres-
sure and oxygenation into a single variable. A reduction in 
OI indicates the “opening” of atelectatic parts of lungs, im-
proved gas exchange across alveolar membranes, and 
shunt reduction. Lungs become more pliant, lowering PIP, 
PEEP, and the risk of lung collapse. MAP may also decrease. 
These changes improve the elimination of carbon dioxide, 
leading to a decrease in PaCO2. Improvement in all mea-
sured parameters in both groups 12 h after treatment indi-
cated that the opened atelectasis remained open and that 
recurrent atelectasis did not occur.
In cases of adhesive atelectasis, the pathological substrate is 
mostly resistant to the treatment consisting of percussion, 
vibration, aspiration, aerosolized bronchodilators, positional 
drainage and fi beroptic aspiration. After mechanical clean-
ing, which is suffi  cient in most cases, in the adhesive type of 
atelectasis recurrent atelectasis mostly appears because of 
the lack and/or dysfunction of surfactant and increased sur-
face tendency. Mechanical ventilation further alters the 
monolayer of surfactant and causes direct alveolar damage, 
exacerbating surfactant defi ciency (5). Being aware of the 
detrimental impact of mechanical ventilation on surfactant 
production, we thought that surfactant administration as 
supplementary therapy might be helpful to our mechani-
cally ventilated patients who developed atelectasis. Our re-
sults are consistent with the idea that therapeutic lavage of 
aff ected lung areas with diluted surfactant minimizes sur-
face tension and improves mucus transport within the nar-
row pediatric airways (9).
TABLE 5. Signifi cance of diff erences in lung function parameters 
between control and surfactant groups at 6 h and 12 h after treatment
Measurements at 6 h
P value
Measurements at 12 h
P value
PIP (cm H2O) 0.041 0.014
PEEP (cm H2O) 0.106 0.000
PaO2/FiO2 (mm Hg) 0.038 0.000
OI 0.115 0.036
SpO2 0.012 0.010
PaCO2 (mm Hg) 0.310 0.034
MAP (cm H2O) 0.007 0.000
PIP = peak inspiratory pressure; PEEP = positive end expiratory pressure; 
PaO2/FiO2 = partial pressure of arterial oxygen/fraction of inspired oxygen 
ratio; OI = oxygenation index; SpO2 = oxygen saturation; PaCO2 = partial 
pressure of carbon dioxide; MAP = mean airway pressure; the level of 
statistical signifi cance was set at P<0.05
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Natural porcine surfactant was used in the present study. 
Natural surfactants, including porcine surfactant, have been 
found to be eff ective in increasing arterial oxygenation and 
alveolar stability, while being less sensitive than artifi cial 
ones to inhibition by serum proteins and other infl amma-
tory mediators (24, 25). Lavage with diluted surfactant 
seems to have advantages over the usual methods of sur-
factant application because it avoids preferential surfactant 
deposition in lung areas without atelectasis, which can fur-
ther increase the ventilation imbalance (11-13). Various con-
centrations of diluted surfactant have been reported in the 
literature (2, 31-33). The concentration in the present study 
(5 mg/mL) was lower than the previously reported ones, 
translating to a mean dose (SD) of 15.66 (2.33) mg surfac-
tant /kg body weight. The greatest limitation in studying 
the eff ects of higher concentrations is the high cost of the 
surfactant.
It is important to note that treatment by lavage without sur-
factant may wash out surfactant from noncompromised 
areas of the lung instead of replenishing the surfactant pool, 
thus further aggravating the patient’s condition. In the pres-
ent study, therapeutic lavage of aff ected areas in both con-
trol and surfactant groups was performed with small vol-
umes, so our approach seems unlikely to generate such 
problems.
CONCLUSION
The results of this study demonstrate that fi beroptic airway 
cleaning is an effi  cient method for atelectasis treatment 
in children, and that simultaneous therapeutic lavage of at-
electatic lung segments with diluted surfactant can im-
prove gas exchange and pulmonary function. For defi ni-
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S A Ž E T A K
Ispiranje bronha surfaktantom kao metoda liječenja 
atelektaze u jedinici intenzivnog liječenja djece
M. Karaman Ilić, G. Madžarac, I. Babić, B. Milavić
Cilj je bio ispitati učinak bronhoskopske primjene razrjeđenog surfaktanta u liječenju atelektaze u djece. U ovu prospektivnu studiju 
je bilo uključeno 18 djece na mehaničkoj ventilaciji koja su neuspješno liječena fi zikalnom terapijom i bronhoskopskom aspiracijom. 
U devetoro bolesnika je nakon bronhoskopske aspiracije apliciran surfaktant u bronh zahvaćenog pluća, dok je u drugih devetoro 
aplicirana jednaka količina fi ziološke otopine. Mjereni su parametri plućne funkcije, PEEP, OI, a radiološka analiza rtg snimki provo-
dila se prije aspiracije te 6 i 12 sati nakon ispiranja. U obje skupine većina mjerenih parametara pokazala je poboljšanje u odnosu na 
osnovne vrijednosti. Skupina kojoj je apliciran surfaktant pokazala je značajno poboljšanje u usporedbi s drugom skupinom. 
Najznačajniji učinak surfaktanta pokazao se na mjerenjima provedenim 12 sati nakon aplikacije (p<0,001 u obje skupine): PEEP 5.22 
(SD 0,44) u skupini ispiranoj fi ziološkom otopinom prema 3.44 (SD 0,73) u skupini ispiranoj surfaktantom; OI 3,84 (SD 1,13) naspram 
2,1 (SD 0,38); srednji talk u dišnom putu (MAP) 8,56 (SD 0,88) naspram 6,33 (SD 0,5). U zaključku, bronhoskopska aspiracija učinkovita 
je metoda u liječenju atelektaze u jedinici intenzivnog liječenja djece. Terapijski učinak ispiranja bronha razrjeđenim surfaktantom u 
takve djece mora se potvrditi u daljnjim istraživanjima na većem uzorku.
Ključne riječi: bronhoalveolarno ispiranje; plućni surfaktant; plućna atelektaza; jedinica intenzivnog liječenja djece
